CAMP
Camp4 Therapeutics Corp
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
No implied move.
Next report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Camp4 Therapeutics Corp
Expected move
No implied move.
Next report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
Camp4 Therapeutics Corp
4.16
Linked news
Camp4 Therapeutics has 3 disclosed suppliers and 4 disclosed customers in SEC filings.
SentenceIn April 2018, we entered into a development and license agreement (the "CMCC Agreement") with Children's Medical Center Corporation ("CMCC").
CAMP 10-Kaccession 0001736730-26-000016
SentenceIn addition, certain of the raw materials for our product candidates are currently provided by a Chinese company, Hongene Biotech, and we expect to rely on this supplier for the foreseeable future on an as-needed basis.
CAMP 10-Kaccession 0001736730-26-000016
SentenceFor example, we rely on a license from the Whitehead Institute for Biomedical Research.
CAMP 10-Kaccession 0001736730-26-000016
SentenceDuring the years ended December 31, 2025 and 2024, we recorded $0.1 million and $0.5 million, respectively, as a reduction in R&D expense in the consolidated statement of operations and comprehensive loss as a result of the earned R&D reimbursement from Eli Lilly.